Call for Late-Breaking Abstracts for the 99th Annual Meeting of the Endocrine Society
The Late-Breaking Abstract Deadline is Monday, February 13, 2017; 1:00 PM EST (US).
Submit your best late-breaking science for oral and poster presentations! ENDO 2017 is the premier venue to share research, exchange ideas, and network with more than 7,500 endocrine researchers and practitioners.
Late-Breaking Abstract Submission Fee
Complete payment information and a NON-REFUNDABLE processing fee of $150.00 (US dollars) are due at the time of submission (VISA, MasterCard, or American Express accepted). The Endocrine Society is registered with www.sam.gov.
Joint Submissions for Cosponsored Meetings
The Endocrine Society is cosponsoring abstract submission and review for the following satellite meetings, to be held in conjunction with ENDO. In addition to consideration for ENDO, authors can also select their abstracts for consideration at any or all of these cosponsored meetings. Regardless of the number of meetings selected, just a single NON-REFUNDABLE processing fee of $150.00 USD will be due at the time of submission.
- 17th Annual Rachmiel Levine-Arthur Riggs Diabetes Research Symposium
At the time of submission, abstracts cannot:
- Contain data previously presented at a national meeting within the US
- Contain data already accepted for publication in any online or PubMed-indexed venue
Violators will be subject to abstract withdrawal, and may be barred from presenting at future Endocrine Society meetings.
Start Your Abstract
By beginning the submission process, you acknowledge that you have reviewed the eligibility criteria above. Failure to comply with any of these rules may lead to an abstract being rejected by the Annual Meeting Steering Committee. Gross violation of research or publication ethics may result in an author's exclusion from future abstract submission.
Abstracts are allowed 2,500 characters, exluding the title, authors, disclosures, and references. Spaces are not counted toward the limit. To ensure your best possible submission, please review these guidelines:
- Guidelines for Submitting a Scientific Abstract
- Guidelines for Submitting Clinical Case Reports
- Submitting Clinical Trial Abstracts
New Eligibility Policy
Abstract submission by non-members no longer requires a member sponsor. Authorship on multiple abstracts is permitted.
Please note: Due to regulations of the Accreditation Council for Continuing Medical Education (ACCME), employees of an ACCME-defined commercial interest may serve as planners/faculty/speakers of accredited CME activities within limited circumstances only. If an employee of a commercial interest is listed as the primary presenter on an abstract accepted for an oral session, the session will be reviewed to determine if the session falls within acceptable scenarios. If it does not, the Endocrine Society may remove CME credit from the session.
Meeting Attendance & Registration
An abstract author must attend ENDO to present their abstract, either as a poster or oral presentation. Submitting an abstract DOES NOT register you for ENDO 2017. Online registration, pdf registration forms, and program information can be found on the Endocrine Society's website.
Until the close of the Call for Abstracts on Monday, February 13, 2017, CONTACT authors will be able to return to this site to edit their abstract. NO REVISIONS will be allowed once the site closes on Monday, February 13, 2017 at 1:00 PM ET.
Abstracts may be withdrawn by sending an email to Carol Balsamo, Senior Specialist, ENDO, at email@example.com, with your submission confirmation number no later than Tuesday, February 21, 2017. The request must be submitted by the contact author. The $150 processing fee will not be refunded.
The submitting author (contact) is responsible for ensuring that ALL co-authors review the abstract and agree to the License Agreement prior to submission. Confirmation of abstract acceptance or rejection will be emailed to all co-authors listed on the abstract. Failure to obtain permission to publish from co-authors may result in abstract rejection.
Abstracts are reviewed, graded and accepted/rejected by the Annual Meeting Steering Committee. Approximately 10% of the top-scoring abstracts from each category are selected for oral sessions. The number of oral session allocations is determined by available space and the number of abstract presenters requesting oral presentation in each category. The remaining accepted abstracts are scheduled for poster sessions.
Abstracts will be published in an online supplement to Endocrine Reviews and in the online ENDO Web Program and ENDO Meetings app. All abstracts are embargoed until the date of their presentation at ENDO.
For help in submitting a submission online, email Tech Support.